Although traditional modes of administration of trastuzumab improve the outcome of HER2-positive breast cancer patients with brain metastases [25, 26], intrathecal administration might represent an alternative to overcome blood-brain barrier [27]. This evidence concerns the gene ERBB2 and breast carcinoma.